We evaluated the susceptibility of 100 Japanese Clostridium difficile isolates to fidaxomicin, a new macrocyclic antibiotic. The minimum inhibitory concentration (MIC) range of fidaxomicin was 0.03-0.5 μg/mL, with a MIC for inhibition of 50% (MIC) of 0.12 μg/mL, and for inhibition of 90% (MIC) of 0.25 μg/mL. We also evaluated the susceptibilities of the same 100 C. difficile isolates to vancomycin, metronidazole, moxifloxacin, clindamycin, meropenem, and ampicillin. Of all the antibiotics tested, fidaxomicin showed the most potent antimicrobial activity against this group of C. difficile isolates. MIC levels against C. difficile isolates, including those producing binary toxin, did not substantially differ from those previously reported in Europe, North America and Taiwan.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jiac.2017.04.008DOI Listing

Publication Analysis

Top Keywords

c difficile isolates
12
antimicrobial activity
8
clostridium difficile
8
isolates
5
mic
5
fidaxomicin
4
activity fidaxomicin
4
fidaxomicin clostridium
4
difficile clinical
4
clinical isolates
4

Similar Publications

Background: Gastrointestinal symptoms are common in patients with COVID-19, but prevalence of co-infection with enteric pathogens is unknown.

Aims: This study assessed the prevalence of enteric infections among hospitalized patients with COVID-19.

Methods: We evaluated 4973 hospitalized patients ≥ 18 years of age tested for COVID-19 from March 11 through April 28, 2020, at two academic hospitals.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!